These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
436 related articles for article (PubMed ID: 25730525)
21. Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia. Kim E; Correll CU; Mao L; Starr HL; Alphs L CNS Spectr; 2016 Dec; 21(6):466-477. PubMed ID: 27629292 [TBL] [Abstract][Full Text] [Related]
22. Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics. Pilon D; Alcusky M; Xiao Y; Thompson-Leduc P; Lafeuille MH; Lefebvre P; Benson C J Med Econ; 2018 Feb; 21(2):135-143. PubMed ID: 28895766 [TBL] [Abstract][Full Text] [Related]
23. [Case of schizophrenia in which depressive and negative symptoms relapsed on switching from oral risperidone to risperidone long-acting injection]. Mori T Seishin Shinkeigaku Zasshi; 2011; 113(10):977-82. PubMed ID: 22187885 [TBL] [Abstract][Full Text] [Related]
24. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. Schreiner A; Aadamsoo K; Altamura AC; Franco M; Gorwood P; Neznanov NG; Schronen J; Ucok A; Zink M; Janik A; Cherubin P; Lahaye M; Hargarter L Schizophr Res; 2015 Dec; 169(1-3):393-399. PubMed ID: 26431793 [TBL] [Abstract][Full Text] [Related]
25. Relapse and long-acting injectable risperidone: a 1-year mirror image study with a national claims database in Taiwan. Su KP; Chang HC; Tsai SJ; Yen FC; Tang CH Value Health; 2009; 12 Suppl 3():S118-21. PubMed ID: 20586973 [TBL] [Abstract][Full Text] [Related]
26. Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden. Mehnert A; Nicholl D; Pudas H; Martin M; McGuire A J Med Econ; 2012; 15(5):844-61. PubMed ID: 22458756 [TBL] [Abstract][Full Text] [Related]
27. Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison. Fu DJ; Bossie CA; Sliwa JK; Ma YW; Alphs L Int Clin Psychopharmacol; 2014 Jan; 29(1):45-55. PubMed ID: 24113628 [TBL] [Abstract][Full Text] [Related]
29. Healthcare utilization and costs of Veterans Health Administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics. Baser O; Xie L; Pesa J; Durkin M J Med Econ; 2015 May; 18(5):357-65. PubMed ID: 25525771 [TBL] [Abstract][Full Text] [Related]
30. Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence. Si T; Li N; Lu H; Cai S; Zhuo J; Correll CU; Zhang L; Feng Y J Psychopharmacol; 2018 Jun; 32(6):691-701. PubMed ID: 29764266 [TBL] [Abstract][Full Text] [Related]
31. Experience with injectable long-acting risperidone in long-term therapy after an acute episode of schizophrenia: the SPHERE Study. De la Gándara J; San Molina L; Rubio G; Rodriguez-Morales A; Hidalgo Borrajo R; Burón JA Expert Rev Neurother; 2009 Oct; 9(10):1463-74. PubMed ID: 19831836 [TBL] [Abstract][Full Text] [Related]
32. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety. Hawley C; Turner M; Latif MA; Curtis V; Saleem PT; Wilton K Hum Psychopharmacol; 2010 Jan; 25(1):37-46. PubMed ID: 20041474 [TBL] [Abstract][Full Text] [Related]
33. Continuation of schizophrenia treatment with three long-acting injectable antipsychotics in South Korea: A nationwide population-based study. Joo SW; Shon SH; Choi G; Koh M; Cho SW; Lee J Eur Neuropsychopharmacol; 2019 Sep; 29(9):1051-1060. PubMed ID: 31362852 [TBL] [Abstract][Full Text] [Related]
34. Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics. Hargarter L; Cherubin P; Bergmans P; Keim S; Rancans E; Bez Y; Parellada E; Carpiniello B; Vidailhet P; Schreiner A Prog Neuropsychopharmacol Biol Psychiatry; 2015 Apr; 58():1-7. PubMed ID: 25448776 [TBL] [Abstract][Full Text] [Related]
35. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder. Greene M; Yan T; Chang E; Hartry A; Touya M; Broder MS J Med Econ; 2018 Feb; 21(2):127-134. PubMed ID: 28895758 [TBL] [Abstract][Full Text] [Related]
36. The prospective economic impact of once monthly paliperidone palmitate versus oral atypical antipsychotics in Medicaid patients with schizophrenia. El Khoury AC; Pilon D; Morrison L; Shak N; Vermette-Laforme M; Amos TB; Kim E; Lefebvre P Curr Med Res Opin; 2019 Mar; 35(3):395-405. PubMed ID: 30526125 [TBL] [Abstract][Full Text] [Related]
37. Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics. Shah A; Xie L; Kariburyo F; Zhang Q; Gore M Adv Ther; 2018 Nov; 35(11):1994-2014. PubMed ID: 30269292 [TBL] [Abstract][Full Text] [Related]
38. Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal. Einarson TR; Maia-Lopes S; Goswami P; Bereza BG; Van Impe K J Med Econ; 2016 Sep; 19(9):913-21. PubMed ID: 27124697 [TBL] [Abstract][Full Text] [Related]
39. Treatment patterns and Medicaid spending in comorbid schizophrenia populations: once-monthly paliperidone palmitate versus oral atypical antipsychotics. Kamstra R; Pilon D; Lefebvre P; Emond B; Joshi K Curr Med Res Opin; 2018 Aug; 34(8):1377-1388. PubMed ID: 29452492 [TBL] [Abstract][Full Text] [Related]
40. Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis. Lafeuille MH; Laliberté-Auger F; Lefebvre P; Frois C; Fastenau J; Duh MS BMC Psychiatry; 2013 Sep; 13():221. PubMed ID: 24016390 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]